{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:04:43Z","timestamp":1790114683412,"version":"4.0.1"},"reference-count":50,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Chronic lymphocytic leukemia (CLL) presents challenges in treatment despite advancements in targeted therapies, often facing resistance or relapse. Chronic inflammation plays a significant role in CLL biology, with heightened inflammatory responses and immune dysfunction. Elevated levels of inflammatory cytokines support this notion. Activating signaling pathways such as NF-\u03baB, Phosphoinositide 3-kinase delta (PI3K\u03b4), and MAPK via B-cell receptors and CD40 confers advantages to leukemic lymphocytes. Our research focuses on the proinflammatory protein S100A9 in CLL progression. We previously described that patients with CLL release exosomes containing S100A9 during disease progression, correlating with NF-\u03baB activation. S100A9, known for its role in autoimmune diseases and cancers, modulates the antitumor immune response by influencing myeloid-derived suppressor cells. Receptors for S100A9 include Toll-like receptor 4, receptor for advanced glycation end products, and extracellular matrix metalloproteinase inducer (EMMPRIN). We identified a novel molecular mechanism involving the S100A9-EMMPRIN interaction in CLL using primary cells and an in vivo CLL mouse model (E\u03bc-TCL1). Additionally, we developed an E\u03bc-TCL1\/S100A9\u2013\/\u2013 mouse model and explored pharmacological targeting of S100A9 in a patient-derived xenograft model, highlighting S100A9 as a promising therapeutic target in CLL with potential clinical applications.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016061","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T20:07:46Z","timestamp":1753733266000},"page":"5219-5233","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Targeting S100A9-mediated inflammation: a novel therapeutic approach for CLL"],"prefix":"10.1182","volume":"9","author":[{"given":"Angimar","family":"Uriepero-Palma","sequence":"first","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elena","family":"M\u00e1rquez","sequence":"additional","affiliation":[{"name":"2Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Payque","sequence":"additional","affiliation":[{"name":"2Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Mediavilla-Varela","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3489-2601","authenticated-orcid":false,"given":"Wael","family":"Gamal","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"},{"name":"3Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2721-1188","authenticated-orcid":false,"given":"Kamira","family":"Maharaj","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3800-2645","authenticated-orcid":false,"given":"John","family":"Powers","sequence":"additional","affiliation":[{"name":"4Department of Tumor Microenvironment and Metastasis, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Chavez","sequence":"additional","affiliation":[{"name":"5Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4458-7192","authenticated-orcid":false,"given":"Erika","family":"Eksioglu","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sernbo","sequence":"additional","affiliation":[{"name":"2Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Palacios","sequence":"additional","affiliation":[{"name":"2Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Querol-Rivas","sequence":"additional","affiliation":[{"name":"2Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Ortega","sequence":"additional","affiliation":[{"name":"6Protein Engineering Unit, Institut Pasteur de Montevideo, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Uria","sequence":"additional","affiliation":[{"name":"2Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gimena Dos","family":"Santos","sequence":"additional","affiliation":[{"name":"2Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay"},{"name":"7Hospital de Cl\u00ednicas, C\u00e1tedra de Hematolog\u00eda, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7782-2024","authenticated-orcid":false,"given":"Carolina","family":"Oliver","sequence":"additional","affiliation":[{"name":"8Servicio de Hematolog\u00eda, Centro de Asistencia Sindicato M\u00e9dico del Uruguay, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana In\u00e9s","family":"Landoni","sequence":"additional","affiliation":[{"name":"9Servicio de Hematolog\u00eda, Hospital Maciel, Administraci\u00f3n de los Servicios de Salud del Estado, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-2275","authenticated-orcid":false,"given":"Eva","family":"Sahakian","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"},{"name":"5Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4194-246X","authenticated-orcid":false,"given":"Pablo","family":"Oppezzo","sequence":"additional","affiliation":[{"name":"2Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur de Montevideo, Montevideo, Uruguay"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[{"name":"1Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"},{"name":"5Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"12","key":"2025102809415044500_bib1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"issue":"4","key":"2025102809415044500_bib2","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1078-0432.CCR-21-1237","article-title":"Recognizing unmet need in the era of targeted therapy for CLL\/SLL: \u201cwhat's past is prologue\u201d (Shakespeare)","volume":"28","author":"Mato","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"19","key":"2025102809415044500_bib3","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1182\/blood-2011-03-342436","article-title":"Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia","volume":"118","author":"Yan","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2025102809415044500_bib4","doi-asserted-by":"crossref","first-page":"13994","DOI":"10.1002\/jcp.28086","article-title":"Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia","volume":"234","author":"Wang","year":"2019","journal-title":"J Cell Physiol"},{"issue":"10","key":"2025102809415044500_bib5","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1590\/1806-9282.20220260","article-title":"Evaluation of cytokine levels as possible predicting elements in patients with chronic lymphocytic leukemia","volume":"68","author":"Khodashenas","year":"2022","journal-title":"Rev Assoc Med Bras"},{"issue":"4","key":"2025102809415044500_bib6","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.4049\/jimmunol.164.4.2200","article-title":"Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells","volume":"164","author":"Furman","year":"2000","journal-title":"J Immunol"},{"key":"2025102809415044500_bib7","doi-asserted-by":"crossref","first-page":"1169397","DOI":"10.3389\/fonc.2023.1169397","article-title":"NF-kB and the CLL microenvironment","volume":"13","author":"O'Donnell","year":"2023","journal-title":"Front Oncol"},{"key":"2025102809415044500_bib8","first-page":"123","article-title":"PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL)","volume":"393","author":"Okkenhaug","year":"2016","journal-title":"Curr Top Microbiol Immunol"},{"issue":"7","key":"2025102809415044500_bib9","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/10428194.2017.1370548","article-title":"Regulation of MAPK signaling and implications in chronic lymphocytic leukemia","volume":"59","author":"Shukla","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025102809415044500_bib10","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood-2017-02-769851","article-title":"S100A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-\u03baB activity during disease progression","volume":"130","author":"Prieto","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2025102809415044500_bib11","doi-asserted-by":"crossref","first-page":"188891","DOI":"10.1016\/j.bbcan.2023.188891","article-title":"S100A8 and S100A9 in Cancer","volume":"1878","author":"Chen","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"10","key":"2025102809415044500_bib12","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1084\/jem.20080132","article-title":"Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein","volume":"205","author":"Cheng","year":"2008","journal-title":"J Exp Med"},{"key":"2025102809415044500_bib13","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.3389\/fimmu.2019.02243","article-title":"S100A9 regulates MDSCs-mediated immune suppression via the RAGE and TLR4 signaling pathways in colorectal carcinoma","volume":"10","author":"Huang","year":"2019","journal-title":"Front Immunol"},{"key":"2025102809415044500_bib14","doi-asserted-by":"crossref","first-page":"1187741","DOI":"10.3389\/fphar.2023.1187741","article-title":"The functions and regulatory pathways of S100A8\/A9 and its receptors in cancers","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"2025102809415044500_bib15","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40364-023-00548-8","article-title":"S100A8\/A9 as a risk factor for breast cancer negatively regulated by DACH1","volume":"11","author":"Zhang","year":"2023","journal-title":"Biomark Res"},{"issue":"6","key":"2025102809415044500_bib16","first-page":"701","article-title":"Predictive value of S100A9 for lymph node metastasis in cervical cancer","volume":"45","author":"Jiang","year":"2020","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"3","key":"2025102809415044500_bib17","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1080\/00365521.2020.1737883","article-title":"S100A9 as a novel diagnostic and prognostic biomarker in human gastric cancer","volume":"55","author":"Zhao","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"11","key":"2025102809415044500_bib18","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1172\/JCI67580","article-title":"Induction of myelodysplasia by myeloid-derived suppressor cells","volume":"123","author":"Chen","year":"2013","journal-title":"J Clin Invest"},{"issue":"10","key":"2025102809415044500_bib19","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1038\/s41375-019-0504-y","article-title":"Elevated expression of S100A8 and S100A9 correlates with resistance to the BCL-2 inhibitor venetoclax in AML","volume":"33","author":"Karjalainen","year":"2019","journal-title":"Leukemia"},{"issue":"1","key":"2025102809415044500_bib20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/s41408-023-00962-z","article-title":"Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in acute myeloid leukemia","volume":"13","author":"Fan","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025102809415044500_bib21","doi-asserted-by":"crossref","first-page":"691705","DOI":"10.3389\/fonc.2021.691705","article-title":"S100A9 derived from myeloma associated myeloid cells promotes TNFSF13B\/TNFRSF13B-dependent proliferation and survival of myeloma cells","volume":"11","author":"Meng","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"2025102809415044500_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1158\/2767-9764.CRC-22-0368","article-title":"S100A8\/S100A9 promote progression of multiple myeloma via expansion of megakaryocytes","volume":"3","author":"Lin","year":"2023","journal-title":"Cancer Res Commun"},{"issue":"4","key":"2025102809415044500_bib23","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1371\/journal.pbio.1000097","article-title":"Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides","volume":"7","author":"Bj\u00f6rk","year":"2009","journal-title":"PLoS Biol"},{"issue":"1","key":"2025102809415044500_bib24","doi-asserted-by":"crossref","first-page":"e005319","DOI":"10.1136\/jitc-2022-005319","article-title":"Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma","volume":"11","author":"Fan","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2025102809415044500_bib51","first-page":"650","article-title":"High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia","volume":"106","author":"Heintel","year":"2005","journal-title":"Blood"},{"issue":"7","key":"2025102809415044500_bib52","first-page":"1216","article-title":"The LPL\/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia","volume":"19","author":"Oppezzo","year":"2005","journal-title":"Leukemia"},{"issue":"7","key":"2025102809415044500_bib25","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3390\/cancers14071676","article-title":"TGF-\u03b2\/SMAD pathway is modulated by miR-26b-5p: another piece in the puzzle of chronic lymphocytic leukemia progression","volume":"14","author":"Marquez","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025102809415044500_bib26","doi-asserted-by":"crossref","first-page":"627020","DOI":"10.3389\/fimmu.2021.627020","article-title":"A detailed analysis of parameters supporting the engraftment and growth of chronic lymphocytic leukemia cells in immune-deficient mice","volume":"12","author":"Patten","year":"2021","journal-title":"Front Immunol"},{"key":"2025102809415044500_bib27","doi-asserted-by":"crossref","first-page":"9797929","DOI":"10.1155\/2022\/9797929","article-title":"Structural and functional properties of activator protein-1 in cancer and inflammation","volume":"2022","author":"Bhosale","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"issue":"10","key":"2025102809415044500_bib28","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V98.10.3050","article-title":"Survival of leukemic B cells promoted by engagement of the antigen receptor","volume":"98","author":"Bernal","year":"2001","journal-title":"Blood"},{"issue":"12","key":"2025102809415044500_bib29","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1182\/blood-2004-07-2669","article-title":"Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells","volume":"105","author":"Petlickovski","year":"2005","journal-title":"Blood"},{"key":"2025102809415044500_bib30","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.3389\/fimmu.2018.01298","article-title":"S100A8\/A9 in inflammation","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"issue":"1","key":"2025102809415044500_bib31","doi-asserted-by":"crossref","first-page":"e2012055","DOI":"10.4084\/mjhid.2012.055","article-title":"Toll-like receptors in chronic lymphocytic leukemia","volume":"4","author":"Muzio","year":"2012","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"suppl 1","key":"2025102809415044500_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00005-016-0433-7","article-title":"The expression of Toll-like receptors in patients with B-cell chronic lymphocytic leukemia","volume":"64","author":"Rybka","year":"2016","journal-title":"Arch Immunol Ther Exp"},{"issue":"1","key":"2025102809415044500_bib33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1158\/0008-5472.CAN-11-3843","article-title":"S100A9 is a novel ligand of EMMPRIN that promotes melanoma metastasis","volume":"73","author":"Hibino","year":"2013","journal-title":"Cancer Res"},{"issue":"4","key":"2025102809415044500_bib34","doi-asserted-by":"crossref","first-page":"6356","DOI":"10.3390\/ijms15046356","article-title":"Importance of N-glycosylation on CD147 for its biological functions","volume":"15","author":"Bai","year":"2014","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2025102809415044500_bib35","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2025102809415044500_bib36","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1158\/1078-0432.CCR-22-2386","article-title":"Duvelisib eliminates CLL B cells, impairs CLL-supporting cells, and overcomes ibrutinib resistance in a xenograft model","volume":"29","author":"Chen","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2025102809415044500_bib37","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.3390\/ijms25031589","article-title":"Treatment of double-refractory chronic lymphocytic leukemia-an unmet clinical need","volume":"25","author":"Zygmunciak","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"22","key":"2025102809415044500_bib38","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2016.66.9697","article-title":"Randomized, double-blind, placebo-controlled phase III study of tasquinimod in men with metastatic castration-resistant prostate cancer","volume":"34","author":"Sternberg","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025102809415044500_bib39","first-page":"223","article-title":"Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer","volume":"7","author":"Gupta","year":"2014","journal-title":"Onco Targets Ther"},{"issue":"12","key":"2025102809415044500_bib40","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.4161\/epi.22674","article-title":"HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance","volume":"7","author":"Van Damme","year":"2012","journal-title":"Epigenetics"},{"issue":"4","key":"2025102809415044500_bib41","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2008.07475.x","article-title":"Expression and function of toll like receptors in chronic lymphocytic leukaemia cells","volume":"144","author":"Muzio","year":"2009","journal-title":"Br J Haematol"},{"issue":"1","key":"2025102809415044500_bib42","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1182\/blood.V97.1.256","article-title":"Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome","volume":"97","author":"Fayad","year":"2001","journal-title":"Blood"},{"issue":"5","key":"2025102809415044500_bib43","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2010-09-307249","article-title":"CCL3 (MIP-1\u03b1) plasma levels and the risk for disease progression in chronic lymphocytic leukemia","volume":"117","author":"Sivina","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2025102809415044500_bib44","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.4049\/jimmunol.1800241","article-title":"Chronic lymphocytic leukemia-derived IL-10 suppresses antitumor immunity","volume":"200","author":"Alhakeem","year":"2018","journal-title":"J Immunol"},{"issue":"13","key":"2025102809415044500_bib45","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"S1","key":"2025102809415044500_bib46","doi-asserted-by":"crossref","first-page":"-3","DOI":"10.13055\/ojhmt_3_S1_03.120221","article-title":"Cell trafficking in chronic lymphocytic leukemia","volume":"3","author":"Davids","year":"2012","journal-title":"Open J Hematol"},{"issue":"3","key":"2025102809415044500_bib47","first-page":"647","article-title":"Molecular mechanisms contributing to glucocorticoid resistance in lymphoid malignancies","volume":"2","author":"Scheijen","year":"2019","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"2025102809415044500_bib48","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/0008-5472.CAN-12-2730","article-title":"Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment","volume":"73","author":"Isaacs","year":"2013","journal-title":"Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5219\/2416868\/blooda_adv-2025-016061-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/20\/5219\/2416868\/blooda_adv-2025-016061-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:42:41Z","timestamp":1761658961000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/20\/5219\/546385\/Targeting-S100A9-mediated-inflammation-a-novel"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":50,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025,10,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016061","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,28]]},"published":{"date-parts":[[2025,10,16]]}}}